Chicago Capital LLC Purchases 2,516 Shares of Insulet Co. (NASDAQ:PODD)

Chicago Capital LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 1.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 171,294 shares of the medical instruments supplier's stock after buying an additional 2,516 shares during the period. Chicago Capital LLC owned 0.24% of Insulet worth $44,984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in shares of Insulet during the 4th quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new position in Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. boosted its stake in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the last quarter. Assetmark Inc. grew its holdings in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares during the period. Finally, Coppell Advisory Solutions LLC increased its stake in shares of Insulet by 135.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after acquiring an additional 162 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent analyst reports. Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Oppenheimer boosted their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Saturday. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Wells Fargo & Company set a $322.00 target price on shares of Insulet in a report on Monday, April 28th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $321.00.

Insulet Stock Down 0.7%

Shares of PODD traded down $2.20 during midday trading on Tuesday, hitting $304.39. The company had a trading volume of 591,849 shares, compared to its average volume of 711,884. The stock has a market cap of $21.42 billion, a price-to-earnings ratio of 52.57, a PEG ratio of 3.62 and a beta of 1.37. The company's 50 day moving average price is $288.34 and its 200 day moving average price is $275.34. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $173.00 and a 52 week high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same period in the previous year, the company earned $0.73 earnings per share. Insulet's quarterly revenue was up 28.8% on a year-over-year basis. On average, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.